Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company, successfully closed its underwritten public offering of 20,010,000 shares of common stock at a price of $5.75 per share. This includes 2,610,000 additional shares issued following the full exercise of the underwriters' option to purchase extra shares. The public offering generated approximately $115.1 million in proceeds before accounting for discounts, commissions, and expenses. Joint book-running managers for the offering were Morgan Stanley, Leerink Partners, Stifel, and Cantor. Trevi is currently developing Haduvio™, an investigational therapy for chronic cough in patients with idiopathic pulmonary fibrosis and refractory chronic cough.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.